Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.76B 11.15B 10.29B 9.49B 17.88B 1,229B 18.27B 123B 48.38B 602B 47.92B 46.87B 2,072B P/E 2026 *
-77x
P/E 2027 * 56.7x
Enterprise Value 12.23B 10.69B 9.86B 9.09B 17.14B 1,178B 17.52B 118B 46.37B 577B 45.94B 44.93B 1,986B EV / Sales 2026 *
8.2x
EV / Sales 2027 * 5.28x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+1.46%
1 week+3.13%
Current month+3.08%
1 month+9.44%
3 months+4.03%
6 months+10.33%
Current year-4.96%
1 week 522.7
Extreme 522.7
560.08
1 month 500.8
Extreme 500.8
569.44
Current year 416.21
Extreme 416.21
598.79
1 year 286.44
Extreme 286.44
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
17/6/26 Free

Director

1,220 0.0053%
17/6/26
Baker Bros. Advisors LP
FreeCompany 4,880 0.0212%
17/6/26 Free

Director

1,220 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
+1.46%+3.13%+65.65%+152.36% 12.76B
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.35%-2.05%+43.05%+180.88% 24.63B
Weighted average by Cap. -2.58%-2.07%+40.90%+143.61%

Financials

2026 *2027 *
Net sales 1.49B 1.3B 1.2B 1.11B 2.09B 144B 2.14B 14.38B 5.66B 70.35B 5.6B 5.48B 242B 2.21B 1.93B 1.78B 1.64B 3.1B 213B 3.16B 21.3B 8.38B 104B 8.3B 8.12B 359B
Net income -205M -179M -165M -152M -287M -19.75B -294M -1.98B -778M -9.67B -770M -753M -33.3B 308M 269M 248M 229M 431M 29.63B 441M 2.97B 1.17B 14.51B 1.16B 1.13B 49.96B
Net Debt -529M -462M -427M -393M -741M -50.96B -758M -5.1B -2.01B -24.96B -1.99B -1.94B -85.92B -1.09B -957M -883M -814M -1.53B -105B -1.57B -10.55B -4.15B -51.63B -4.11B -4.02B -178B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
17/07/26 USD 553.48 +1.46% 528,309
16/07/26 USD 545.53 -0.86% 238,337
15/07/26 USD 550.25 +2.49% 264,309
14/07/26 USD 536.86 +1.10% 241,715
13/07/26 USD 531.00 -1.06% 287,887
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
553.48USD
Average target price
678.86USD
Spread / Average Target
+22.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock